BTK-Inhibitoren und ihr Effekt auf autoimmunologische ZNS-Krankheiten

García-Merino A. Bruton's Tyrosine Kinase Inhibitors: a aew generation of promising agents for multiple sclerosis therapy. Cells. 2021; doi:10.3390/cells10102560

Jayagopol LA, Zabad RK. Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis. The missing link for treatment optimization? Pract Neurol. 2022;22(2):29-32

Reich DS et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2021;20(9):729-38

Cohen S, Tuckwell K, Katsumoto TR et al. (2020). Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial. Arthritis Rheumatol. 2020;72:1435-46

ACTRIMS 2019. - Late Breaking News Posters. Mult Scler. 2019;25:157-65

Gracia P, de Gallego BI, Rojas B et al. Automatic counting of microglial cells in healthy and glaucomatous mouse retinas. PLoS ONE. 2015;10:1-16

Frenger MJ, Hecker C, Sindi M et al. Semi-automated live tracking of microglial activation in CX3CR1GFP mice during experimental autoimmune encephalomyelitis by confocal scanning laser ophthalmoscopy. Front Immunol. 2021;12:1-10

Yong HY, Yong VW Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2022;18:40-55

Geladaris A, Torke S, Weber MS. Bruton's Tyrosine Kinase Inhibitors in multiple sclerosis: pioneering the path towards treatment of progression? CNS Drugs. 2022;36:1019-30

Owens TD, Smith PF, Redfern A et al. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci. 2022;15:442-50

Haselmayer P, Camps M, Liu-Bujalski L et al. Efficacy and pharmacodynamic modeling of the BTK Inhibitor Evobrutinib in autoimmune disease models. J Immunol. 2022; doi:10.4049/jimmunol.1800583

Montalban X, Arnold DL, Weber MS et al. Placebo-controlled trial of an oral BTK Inhibitor in multiple sclerosis. N Engl J Med. 2019;380:2406-17

Dhillon S. Orelabrutinib: first approval. Drugs. 2021; doi:10.1007/s40265-021-01482-5

Zhang B, Zhao R, Liang R et al. Abstract CT132: Orelabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor with superior safety profile and excellent PK/PD properties. Cancer Research. 2020; doi:10.1158/1538-7445.AM2020-CT132